Isarna Therapeutics snags $17.8 mln
Isarna Therapeutics said Tuesday that it has secured $17.8 million in funding from AT NewTec and existing investor MIG. Based in Munich, Germany, Isarna is developing TGF-β inhibitors to fight cancer.
7 January 2014•2 mins read
